Literature DB >> 11932664

Safety and efficacy of femoral-based hemodialysis access grafts.

David B Tashjian1, George S Lipkowitz, Robert L Madden, Jeffrey L Kaufman, Sang Won Rhee, Joel Berman, Marc Norris, Jane McCall.   

Abstract

OBJECTIVE: Arteriovenous fistulae traditionally have been placed in the upper extremity. Experience with groin hemodialysis access has been discouraging because of high infection rates and associated limb amputation. We reviewed our experience with angioaccess grafts in the groin to assess safety and viability in our hemodialysis patient population.
METHODS: A retrospective review was performed of all groin hemodialysis access grafts placed at a single tertiary care center between June 1990 and February 1998. Demographics, complications, and subsequent treatment were recorded. Graft patency and infection rates were analyzed with life-table analysis.
RESULTS: Data were collected on 73 graft insertions. A total of 52 episodes of thrombosis occurred in 26 grafts. Primary patency rate was 71% at 1 year. Secondary patency rate was 83% at 1 year. There was a 22% incidence rate of infection.
CONCLUSION: We conclude that the incidence rate of infection and thrombosis in our series of femoral-based hemodialysis grafts is comparable with rates reported in the literature for upper extremity polytetrafluoroethylene angioaccess grafts. Although not considered a first choice, femoral artery-based hemodialysis access is a viable option when arteriovenous fistulae in the upper extremity cannot be constructed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932664     DOI: 10.1067/mva.2002.121750

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

1.  Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft.

Authors:  Eunsun Oh; Yong Jae Kim; Dong Erk Goo; Seungboo Yang; Seongsook Hong
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

Review 2.  Lower Extremity Permanent Dialysis Vascular Access.

Authors:  Vishal B Parekh; Vandana D Niyyar; Tushar J Vachharajani
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-27       Impact factor: 8.237

3.  Single center review of femoral arteriovenous grafts for hemodialysis.

Authors:  Michael J Englesbe; Wajd N Al-Holou; Alice T Moyer; Jessica Robbins; Shawn J Pelletier; John Magee; Randall S Sung; Darrell Campbell; Jeffery D Punch
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

4.  Thigh grafts contribute significantly to patients' time on dialysis.

Authors:  Sunanda J Ram; Bharat A Sachdeva; Gloria C Caldito; Gazi B Zibari; Kenneth D Abreo
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-22       Impact factor: 8.237

5.  Ultrasound-guided femoral dialysis access placement: a single-center randomized trial.

Authors:  Mayoor V Prabhu; Deven Juneja; Palepu B Gopal; Mohan Sathyanarayanan; Sreepada Subhramanyam; Sridhar Gandhe; K Shivanand Nayak
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

6.  Outcomes of two different polytetrafluoroethylene graft sizes in patients undergoing maintenance hemodialysis.

Authors:  R Afshar; S Sanavi; S Afshin-Majd; A Davati
Journal:  Indian J Nephrol       Date:  2009-10

7.  Long-term outcomes of arteriovenous thigh grafts in hemodialysis patients: a comparison with tunneled dialysis catheters.

Authors:  Song Ong; Jill Barker-Finkel; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

8.  Long Term Outcomes of Arteriovenous Grafts for Hemodialysis in Lower Extremities.

Authors:  Seok Han; Dan Song; Sangchul Yun
Journal:  Vasc Specialist Int       Date:  2016-12-31

9.  The comparison of the complications of axillobrachial and femorofemoral arteriovenous shunt prostheses in hemodialysis, a 3 year study in Alzahra general hospital.

Authors:  Hafez Ghaheri; Mohamad Reza Lavasanijou; Ali Akbar Beigi; Afrooz Eshaghian; Mojtaba Akbari
Journal:  Adv Biomed Res       Date:  2013-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.